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Knowledge about the relationship between the structure of genes and biological function has increased rapidly over the past twenty years, clarifying the importance of genetics in human health and disease. Advances in molecular genetics and DNA technology and their uses in medicine have created new challenges for both the conduct and review of human subjects research. Continuously developing technologies are presenting unfamiliar issues concerning risk, consent, and disclosure. Institutional review board members have begun to ask whether or how genetics protocols fit into the ordinary review structure. Do they raise novel medical, ethical, or legal questions? And if so. how can we accommodate them in the context of protocol review?
In the ordinary course Of its review, an IRB evaluates such issues as the validity and value of the research, subject eligibility criteria and recruitment strategies, trial design, quantification or prediction of risks and benefits. disclosure to subjects, privacy and confidentiality, subject follow-up requirements, and monitoring.
1,2 The challenge in their review of genetics research is to recognize when a particular protocol raises new issues, and if so, whether they are addressed appropriately by the investigators. IRBs must be prepared to address these issues before recommending approval, amendment or disapproval of protocols.
We have designed this article to assist investigators and IRB members in their review of gene localization and identification protocols, sometimes referred to as "gene hunting" research. We provide a general description of "gene hunting" studies, set out a checklist/critical path identifying issues for IRB review (table 1) , and discuss in greater detail several points of controversy raised by this kind of research. A glossary of terms that have not been defined in the body of the text is also provided (table 2) . Throughout the article, we cite materials for readers seeking further information.
Gene Localization and Identification Protocols
All gene localization and identification studies share the common goal of placing information about human genes in a systematic linear order according to their relative positions along each chromosome. The intent of these studies is to identify genes that cause or contribute to a disease or trait. This is typically done first by finding the approximate chromosomal position of the gene ("mapping"), and then by determining the identity of the gene. This "mapping" of the genes takes two different forms: recombination-based maps (typically termed linkage maps) and physical maps.
Genetic linkage maps show the distance between and relative order of genes on the chromosomes. Most frequently. research begins by studying families and measuring the frequency with which a well-defined genetic marker cosegregates with, or is linked to, the phenotype. The marker paves the way for the eventual identification of the genetic defect or characteristic by focusing attention on a restricted portion of the genome.
3 Association studies are also used to test whether a particular allele occurs at a higher frequency among affected compared with unaffected individuals. These studies determine correlation of the allele with a trait in unrelated, rather than related, individuals. 4 Recombinant DNA technology has brought about an efficient way to make genetic linkage maps using the natural differences in DNA sequences (polymorphisms) as a way to track chromosomes through a family. Restriction enzymes recognize specific short nucleotide sequences and cut the DNA at those sites. One can then Table I : Schema for IRB Review of "Gene-Hunting" Protocols
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Background and Justification
What questions does the research address? Has the investigator demonstrated that the research has scientific or medical value? How does the proposed study relate to previous work? Does it provide a rational continuation of this work?
If not, have the innovative aspects been adequately justified?
Research Design
Is the scientific method to be employed valid? 45, 46 Has it been used previously, and if so, how has it been assessed? What quality controls are built into the method?
47
Is the planned statistical analysis appropriate: i.e., is it likely to provide valid and unbiased answers to the study question?
* If a full genome scan is planned, Does the sample size provide sufficient power to identify one or more loci with a reasonable degree of certainty?
Are population specific allele frequencies already known? If not, how will they be determined?
* If a trait to be mapped is complex, will robust nonparametric methods of analysis (which do not necessarily require a Mendelian genetic model_ be used first?
If not, is there good justification for this?
* If the study is a case-control study, are the cases and controls carefully matched for ethnicity? * Is there adequate consideration and/or statistical correction for multiple comparisons (which may number in the hundreds for genome scans), and is the procedure to be used described clearly?
Procedures
What procedures are involved in the study (e.g., medical examinations, blood draws, tissue/tumor donation, questionnaires, interviews, etc.)? How many? How often? How much time will they take?
Are all of the procedures in this study required to answer the research question? Can any be eliminated?
Will procedures for obtaining or maintaining information involve a data/DNA bank? Is stored tissue involved? Will the data/DNA be destroyed at any point? Will identifiers be maintained with the stored data/DNA? [48] [49] [50] * Will subjects be asked to allow investigators to contact them in the future for more information or to participate in further research? 51 * Who will have access to information about those studied (including information about "nonparticipating" family members 52 )? Will informed consent be sought to use the data/DNA in other studies? Under what conditions, if any, will data or DNA be released to other investigators? * Are the procedures for maintaining confidentiality of data/records/database information specified clearly (e.g., encryption, use of unique identifiers, sequestering of records, security measures)? Are they adequate?
53
Subject Selection
How is the study population defined? Does it include affected and/or unaffected individuals, related or unrelated? Are healthy controls included?
Have the eligibility criteria been justified? Do they strike a defensible balance between scientific validity and generalizibility? (I.e., is the study population sufficiently restricted to yield interpretable results without being unduly restrictive?) How are subjects to be recruited? Will they be remunerated'?
If so, is the amount or nature of the remuneration appropriate?
* If the study involves families, how will family members be recruited? By the proband?
52 By the family physician? Through support groups or lay organizations? By investigators directly? * Will the proposed recruitment process place undue pressure on other family members to participate? 28 * Might recruitment itself "inflict" unwanted information about risk status on family members? 31 Are adequate procedures in place to protect the interests of these people? * Does the protocol involve "nonparticipating" family members about whom subjects will provide personal/medical information? 52 Does the protocol include incompetent subjects (young children or incompetent adults)? Is there a valid alternative to their participation in this protocol?
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If not, have provisions been made for assent and/or proxy consent? 55, 56 Does the protocol involve other vulnerable populations (e.g., patients with Alzheimer disease or psychosis who have periods of fluctuating competence)? Have their special needs been taken into account? 56, 57 
Risks and Benefits
Is the importance of the research question sufficient to justify risks associated with the procedures specific to the research (i.e., the dedicated research procedures)? 58, 59 Have risks been minimized to the extent possible? * Will participation in the protocol result in any benefit to subjects? Will the results have any predictive value for subjects in terms of life or health choices (e.g., marriage, reproductive choices, choice of employment, medical treatment, disease prevention)? * Are instances of nonpaternity 61, 62 or incest likely to be uncovered by the research? How will these be handled (e.g., disclosure of the possibility in consent materials, withdrawal of the samples from the research)? * Will the knowledge gained by the subjects about their current or future health or their carrier status pose additional risks to them. such as risks to insurability, 63 employability, immigration, paternity suits, or social stigma? 52 Have adequate provisions been made for privacy and confidentiality of subject information, including for "nonparticipating subjects"? * Could the research result in stereotyping or stigmatizing a particular community or cultural group? Have investigators taken steps to approach the group involved and solicit comments where appropriate? 16,17.20,21 *Will a family pedigree be published? Will the method or occasions of publication or presentation of findings contain the potential for identifying family members? 52, 64 If so, have the affected individuals given consent to the publication or presentation of private information about them
Information to Subjects
Does the information provided to prospective subjects adequately inform them of what is being studied and why, details about study procedures, known risks and benefits as well as uncertainties about risks and benefits, and alternatives to participation? * If there is no individual benefit to subjects, has this been disclosed? * Have subjects been told of their right to withdraw from the research without penalty or loss of benefits to which they are otherwise entitled? 66 Have they been advised of any consequences of withdrawal? Are there any limitations on the ability of subjects to withdraw their data or DNA samples?
If so, has this been adequately disclosed? 67, 48 * Is it clear to subjects what information will be revealed to whom and under what circumstances (e.g., participants may learn about other family members' risk status)? *Will subjects be informed of any special risks associated with the study (e.g., changes in family relationships, risks to privacy, confidentiality, insurability, employability, immigration status, paternity suits, educational opportunities)? 52, 63 * Will the general study results be made available to subjects? 33 * If no immediately useful or interpretable information of relevance to subjects is likely to result from the study, has this been adequately explained?
*If information that is clinically relevant to subjects is likely to result, will counselling by genetic counsellors be made available? * Have subjects been given the option of individually choosing not to receive their study results? * Could other clinically relevant information be uncovered during the study? If so, how will it be disclosed to subjects? Who will disclose it (e.g., investigators, genetic counsellors, the family physician)?
Will there be any costs associated with participating (including the cost of genetic counselling or psycho/social counselling) that are not covered by the investigator or the institution? If so. has this been disclosed?
67
Commercial Interests
* Does anyone have a commercial interest in the research?
If so, who (e.g., third parties, the investigator)? Have the subjects been informed of these commercial interests? 68, 48 * Where commercial products may eventually be developed from biological materials removed from the subjects in the course of the research, will subjects be asked to waive any rights or control over the tissue'?
If they refuse, will they be allowed to participate? determine whether alterations in the DNA being compared correlate with the inheritance of the disorder or characteristic under study. [5] [6] [7] [8] physical maps are derived mainly from chemical measurements made on the DNA molecules that form the human genome. They represent the location of identifiable landmarks in genome with restriction enzymes and the DNA For the human genome, the ordering the resulting DNA segments physical map of lowest resolution is as they were ordered originally on the found in the banding patterns of the chromosomes (contig mapping). The 22 autosomes and the X and Y chro-physical map of highest resolution is mosomes that may be observed using the complete nucleotide sequencing a light microscope. High resolution of the human genome, showing the maps can be made by cutting up the actual position. size, order, and num-
IRB Table 2. Glossary of Terms Not Defined in the Text
allele -alternative forms of a gene at a particular locus. autosome -any chromosome other than a sex chromosome. chromosome -the circular DNA structure molecule containing a linear, end to end arrangement of genes with instructions essential for the life of the cell. contigs -groups of clones representing overlapping (contiguous) regions of a genome. cytogenetic mapping -treatment of chromosome by staining to show patterns of light and dark bands that are unique for each human chromosome, allowing for the definition of each chromosome. demarcated or dedicated research -any part of a research protocol that relates only to the research, and not to any therapy or intervention the subject would have in the ordinary course of DNA: deoxyribonucleic acid -a double stranded molecule [held together by weak bonds between base pairs of nucleotides] that encodes genetic information. electrophoresis -a method of separating a mixture of molecules by passing an electric current through a medium containing the molecules; each molecule travels through the medium at a different rate depending on its electrical charge and size. gene -the fundamental physical and functional unit of heredity, constituting an ordered sequence of nucleotides located in a particular position on a particular chromosome. genome -the entire DNA sequence of an organism containing its complete genetic information. genome scan -a research technique using known genetic markers to search an individuals' entire DNA sequence. hybridization -the process of joining together two complementary strands of DNA and RNA, or two strands of DNA, to form a double stranded molecule. in situ hybridization -finding the location of a gene by adding specific relative probes for the gene and detecting the location of the radioactivity of the chromosome after hybridization. nucleotide -a subunit of DNA or RNA consisting of a nitrogenous base, a phosphate and a sugar called ribose or deoxyribose. The arrangement of the nucleotide sequence along the DNA is called the DNA sequence. obligate carrier -an individual who, on the basis of pedigree analysis, must carry the allele in question. pedigree -a diagram of a family history indicating family members, their relationship to the proband, and their status with respect to a particular hereditary trait or condition. phenotype -the observable physical expression of a particular gene or combination of genes, or of the interaction of genotype with the environment. polymorphism -difference in DNA sequence among individuals. proband -the affected person through whom a pedigree is discovered or explored. restriction enzyme -a protein that can cut double stranded DNA at a specific nucleotide sequence. RNA: ribonucleic acid -a chemical found in the nucleus and cytoplasm of cells; a single stranded nucleic acid similar to DNA, but with ribose sugar rather than deoxyribose sugar and uracil rather than thymine as one of its bases. somatic cell hybridization -fusing cells, usually from different species, together. somatic cell -any cell of an organism that is not in the germline. ber of base pairs between and within the genes.
9 Physical mapping is accomplished by a variety of means, including in situ hybridization. somatic cell hybridization, electrophoresis, gene product dosage detection, cytogenetic mapping, and radiationinduced breakage of chromosomes.
There is no single, ready review model that will be appropriate for every protocol or every IRB. In the schema provided in table 1, we have suggested a number of questions that will be relevant for many gene localization and identification studies. Not all IRBs will have the expertise to deal with all of the questions posed, in which case they should consult specialists in appropriate disciplines in undertaking their review. Questions of particular relevance for gene localization and identification protocols are marked with an asterisk.
Discussion
While the review of gene localization and identification studies raises many ethical issues, we limit the discussion below to several controversial ones.
Evaluating a Protocol's Validity and Value. Scientific worth is a prior condition for the ethical conduct of research.
10 Evaluating the worth of a protocol requires consideration of both the soundness of its results (validity) and the importance of its hypothesis (value). The ability of the study architecture and the analytic strategy to appropriately address the research question(s) posed is a prerequisite for an internally valid scientific investigation. Gene localization and identification studies pose some special questions for the evaluation of validity and value.
As with nongenetic studies, to ensure the validity of research results in "gene hunting" protocols, IRBs must evaluate the concordance between the hypothesis and methodology used. A research design that leads to false conclusions may be unethical because actions based upon those conclusions may have adverse consequences.
11 Invalid research also raises ethical issues of justice if scarce resources are wasted.
While questions of methodology are relevant to all protocols, genome research raises a number of special concerns. For example, having sufficient human subjects or other experimental materials available to ensure that the study will have the desired precision, or statistical power, is at issue in essentially all studies. However, inclusion criteria for a pedigree study create an extremely narrow group of potential subjects who are not interchangeable in the same way subjects in other protocols may be. IRBs need to ask how valid the results will be if investigators do not succeed in recruiting everyone they have identied. Another factor affecting subject selection relates to how carefully cases and controls must be matched for ethnicity in a "gene hunting" study using this design. Expertise in research design and statistics as well as background knowledge in genetics will be required to evaluate a protocol's validity. IRBs lacking such expertise must call on outside consultants to assist their review. Again, however, this does not constitute a radical departure, or in fact any substantive departure from what should already be IRB practice. Committees frequently need to supplement their membership for the review of certain protocols. Although genome studies pose special challenges, IRB members should not be hesitant to approach their review in the same critical manner that they bring to evaluating other studies. In particular, they should resist the temptation to defer automatically to the "experts."
A study may meet the criteria of scientific validity without being of any value or significance. This value need not be an immediate medical or social benefit for the subjects who are recruited if the results are scientifically valuable. The results of some research may be preliminary, requiring further work for elaboration or confirmation. With gene localization and identification studies, the knowledge generated may be a prerequisite to understanding the alteration in function seen in a genetically linked disease. Yet the study results will likely have no Immediate clinical relevance. Nor will they necessarily or immediately result in additional studies directed toward health management. At the same time, some of these studies expose participants to the risk of social or economic harm from the information generated about them. In fact, the research results may have a negative impact upon (or "disvalue" for) certain individuals or groups who are not necessarily research subjects. For example, looking for genetic concomitants to medical disorders such as breast cancer or Alzheimer's disease in certain ethnic groups presents risks not only to the individual research subjects but to the entire community of which they are members. The same may be true for research linking genetics and behavioral disorders.
Is it within the IRB's mandate to evaluate the wider social impact, positive or negative. of a protocol? Should it ask whether the proposed research has sufficient value to offset any risks, not just to the subjects, but to wider populations? United States regulations appear to answer these questions in the negative, stating that the IRB should not consider as "research risks over which it has responsibility" the possible long-range effects of applying the knowledge gamed in the research. The effects of the research on public policy are cited. as an example (45 CFR 46.111(a) ). While there are indications that this requirement was established specifically to deal with social science research, 12 to the contemporary reader, the regulations as written reflect a model from clinical treatment-that of the physician and patient in a private relationship of two autonomous individuals. While such a model may be appropriate for protocols in which the risks are borne entirely by the individual subject, it may not serve well in the context of some genetics protocols, where the adverse impact may be felt by other individuals or an entire community. Ethics guidelines for social science research that require attention to the welfare and integrity not only of the individual subject, but of the particular collective. may be helpful. [13] [14] [15] Risks to subjects and families and to wider communities can be reduced (though not eliminated) with stringent requirements for confidentiality of information or, where appropriate, collaboration with community groups in trial design and procedures for disseminating results to minimize any adverse impact. [16] [17] [18] [19] [20] [21] [22] Just as questions concerning the evaluation of research methodology may require special expertise, so also might the evaluation of a protocols potential value. Judgments of value must include a view about the significance of the hypothesis itself for reasons of its novelly, clinical and/or scientific interests, and also for any other social implications.
10 This requires the participation of an interdisciplinary group, going beyond clinical and scientific expertise to include those with experience in law and ethics as well as representatives of the community in general. As with nongenetics protocols where outside consultants may be needed to supplement the expertise of the IRB, some aspects of the value or negative impact of a "gene hunting" protocol will best be judged by the individuals or the community that will be affected. Lack of direct benefit to participants coupled with the potential for risk to them or to others gives special importance to questions of value in an IRB's analysis or the risk/benefit balance for any individual gene localization and identification protocol.
Genetics and the Family. The existing paradigm of research ethics is the autonomous individual who makes an informed choice about participation. This paradigm emphasizes the importance of full disclosure of material information to prospective subjects, who should be free to make their choices without undue influence, coercion, or pressure. Although there are instances in which there will be direct consequences for others, entering a trial is considered to be a fundamentally private choice, affecting each subject individually.
Many genetics protocols challenge this paradigm in at least two ways. First, genetic information is by its nature information about families. Detecting a genetic mutation in one person can, for example, give information about the risk-status of family members who did not participate in the study. Second, cooperation of family members may be relevant to obtaining information that is key to the success of the research. This is particularly true in "gene hunting" studies in which there is no direct genetic test available for the gene in question and genetic markers are used. For a successful study, not only must family members be willing to participate, in some research they must also agree to share information about their genetic constitutions with other family members as well as with investigators. This is the case where studies reveal information about the obligate status of genetic carriers within the family.
For Wertz and Fletcher, an ethics of care is more useful than an autonomy-based approach in dealing with genetic information. Such an ethic implies that patients should be dealt with "in terms of interactive relationships." 23, 24 Under an ethics of care, for example, there is a more extensive duty to inform family members of genetic risks. As part of a family, we may be morally required to make decisions on the basis of thinking about what is best for all concerned, not simply what is best for ourselves.
25
The Danish Council of Ethics goes so far as to suggest that since genetic information can be of crucial importance for allowing others to make appropriate health care decisions, genes are, in a way, a part of the "public domain."
26
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While genetic research certainly challenges our traditional notions of the autonomous individual as research subject, we are not convinced that any moral obligation family members may have toward each other is enforceable, particularly by investigators or IRBs. This is the case even where the research in question could potentially lead to life-saving preventive or therapeutic strategies. Coercion would be a serious deviation from one of the most fundamental principles of medical ethics.
In the absence of a paradigm that could protect subjects as well as "voluntary informed choice" while at the same time incorporating notions of interactive relationships and family solidarity, we can highlight several elements that IRBs should consider in their review of protocols requiring the participation of families.
Pressure on family members to participate in protocols. While enforcement of family obligations is clearly outside an investigator's or IRB's mandate, the family context of genetic research remains ethically relevant. Genetic research involves close personal relationships entailing a range of actions and emotions-love, affection, obligation. gratitude, jealousy, advice, support, criticism, fear of disapproval, argument, security, or insecurity. No one can control how families will deal with genetic issues, nor can they predict individual coping strategies. 27 Is there a role for IRBs to play in mitigating potential family stress from pressure to participate in pedigree or other genetic studies?
Appelbaum and Lidz distinguish between pressures that affect human behavior so extremely as to deprive it of legal consequences, and those pressures that form a necessary component of socialization and education. "Human interaction can never be free of pressures that one person consciously or unconsciously places on another. Many pressures are inherent in such interaction and constitute a normal and often desirable part of relationships." 28 These pressures exist naturally within families and are often intended to influence another's behavior. An IRB should not be concerned with eliminating family interactions, including those that are characterized as persuasion, manipulation. or even pressure, but with minimizing opportunities for going beyond this natural boundary by using undue influence or coercion that inhibits a voluntary consent to participate.
Making judgments concerning the nature of pressures is difficult because of individual family dynamics and the impact of context on a particular action. Actions that might be coercive in one family or circumstance might not be in an another. Discussions family members might have with one another may be completely appropriate, whereas the same conversations would not be appropriate if they involved an investigator and prospective subjects. IRBs would therefore have difficulty establishing policies that define in advance what any particular family member might perceive as coercive.
29 They can, however, impress upon investigators their obligation to inform prospective subjects in a nonthreatening. noncoercive manner. Where a protocol calls for family members to inform relatives about the study, the information they present should emphasize that each individual has the right to choose whether to participate. Where there are obvious reasons to suspect coercion or undue influence, investigators could explore with potential subjects their motivation for participation. Obviously the desire to help a relative is not an automatic indication of coercion. Such a motive may be purely altruistic.
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Unwanted information and the right "not to know." In the ordinary course of recruiting. prospective research subjects are given information concerning, among other things, the potential risks and benefits of participation. A subjects informed choice to enter a trial, knowing the disclosed potential harms that might (or might not) materialize, is a prerequisite for the ethical conduct of research. But what if the recruitment process itself has the potential to harm a prospective subject, before that subject has the opportunity of choosing whether to participate? Such may be the case where family members are recruited into gene localization or identification studies. Persons who are unaware of the incidence of a disease in their family, who have not sought information concerning their own risk of developing the disease based on family patterns, or who may resolve their anxiety or emotional conflict by denying that the disease is an issue for them. may have a right "not to know" they and their families are at risk.
31 Some protocols by their design would impinge upon this right in the recruitment process, thus causing harm to those who have not agreed to bear the risk of such harm. "Inflicting" unwanted information about risk status on family members could conceivably pose risks for privacy, confidentiality, employability, insurability, immigration status, paternity suits, as well as create the potential for a duty to warn relatives of at-risk status.
Protocol implementation may also disturb family secrets, either contemporary or from past generations. that could affect a genetic analysis. Facts such as adoption. incest. artificial insemination, nonpaternity, pregnancies, or permanent institutionalization because of mental illness are frequently hidden from at least some family members. Participation in research should not jeopardize family relationships by imposing information on those who have not sought to have it: nor should it "extract" secrets from those unwilling to share them.
The issue of harm is particularly sensitive in gene localization and identification studies since for the most part participation offers subjects no benefit beyond the opportunity for altruism. For those who choose not to participate, yet are burdened unwillingly with information, the issue of harm is even more difficult. While investigators should use the most sensitive recruiting techniques possible, the potential for this harm cannot be eliminated completely. This fact should alert IRBs to the necessity for careful review of the protocols value, as discussed above, and the need to preserve confidentiality.
Research Subject Access to Test Results. In the context of research, the principle of respect for persons entails not only the right to informed consent, but also subjects' right to information about themselves, including, in at least some cases, test results. But the principle of respect for persons is tempered by the principle of beneficence: the decision to disclose test results must involve a consideration of the risks and benefits of disclosure. Geneticists have exhibited a strong commitment to both principles and to the sharing of genetic information with research participants. Some geneticists-perhaps taking the principle of respect for persons to its extreme-believe that test results must always be disclosed at the subject's request, even when the meaning of a test result is uncertain. 32 The rationale for disclosing test results to subjects discussed below cuts across both "gene hunting" protocols and genetic screening research.
Reilly, among others, argues convincingly that the decision to disclose the results of a genetic test in the context of research must involve some consideration of the harms and benefits of disclosure as well as the accuracy of the test information. 1, 2, 33 He argues that the IRB policy on disclosure in an individual study should be based on consideration of at least three factors:
(1) the magnitude of the threat posed to the subject, (2) the accuracy with which the data predict that the threat will be realized, and (3) the possibility that action can be taken to avoid or ameliorate the potential injury. Based on this analysis, test results can be grouped into results that must be disclosed, those that may be disclosed, and those that ought not to be disclosed. Unfortunately, Reilly does not define precisely how the above factors map onto these categories. He does say that if the conclusion of this process is that participants will not be informed of a test result, this fact must be disclosed in the consent form.
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While this sort of calculus can be applied to any individual study, can we define a set of cases in which in principle test results ought not be disclosed? One conceivable approach is that the results of tests that are not clinically validated should not be revealed. One might argue that experimental tests are by definition under development, and subjects ought not to be informed of the result of such tests until the risks, benefits, and validity of such tests are fully documented, as evidenced by their adoption in clinical practice. This approach is untenable, in part because the evaluation of the risks and benefits of test-result disclosure is a crucial part of the evaluation of genetic tests. 34 Furthermore, the criterion fails to take into account the fact that some experimental genetic tests may reveal information that calls for action. For example, while not enough is known about the efficacy of prevention strategies for women carrying the BRCA1 gene, a woman with the gene certainly requires close medical follow-up and the option of unproven prevention strategies (mammography, mastectomy, tamoxifen) ought to be discussed with her. is no corresponding obligation to disclose results. We suggest that studies, studies involving a population in which the association between this threshold be defined as data genotype and disease is not estabthat are sufficiently clear in clinical implications to affect the lished, and those where the subjects' medical care of the subject.
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genotypes at the many marker loci are not found to be linked to the a blanket criterion, seems untenable. Even if a test result has no direct clinical implications (i.e., there are no known prevention strategies). subjects may nonetheless benefit from information that reduces uncertainty regarding the condition for which they are at risk. Wiggins and colleagues followed subjects who were informed of being at lesser or greater risk of Huntington disease (a disease for which there is no known treatment, preventive or otherwise). 38 As one might expect, subjects informed that they were at decreased risk for the disease showed a substantial decline in distress. Surprisingly, even subjects who were informed that they were at increased risk showed small decreases in distress and depression. Roughly 10 percent of both groups experienced severe psychological distress. 39, 40 Thus, the standard proposed by Kodish and colleagues does not seem workable in all cases.
Upon examination. this stance, as
Given the failure of the above two criteria, we are left with a restricted set of cases in which disclosure would be inappropriate: test results that are uninformative. If respect for persons implies a right to medical information, this cannot include a right to test results that are not "information." When a test is so preliminary that results are unlikely to affect the individual's risk assessment, the subjects autonomy is not furthered by knowing these results. Such circumstances are, of course, not uncommon in "gene-hunting" studies. 41 Obvious cases in which test results are unlikely to be informative include: preliminary linkage or association tee of which one of us was a member) provides a useful illustration of how such a case might be handled by an IRB. The study in question proposed to examine the association between apolipoprotein-E and Alzheimer disease (AD) in a cohort of Jewish and French-Canadian individuals.
42 Although the association between APO-E4 and Alzheimer disease is fairly well established, the association had not been documented in this patient population. 43, 44 Indeed, a pilot project by the study investigators (with 40 patients) failed to reveal any association between APO-E4 and Alzheimer disease in this population. The study planned to enroll 100 persons with Alzheimer disease, 100 with cognitive impairment not yet diagnosed, and 288 age-matched healthy controls. All subjects would be tested for the APO-E genotype. disease gene.
One study (reviewed by a commitBelieving that research participants have a right to know their own test results, the investigators planned to inform subjects of their APO-E status. The IRB questioned the propriety of disclosing results to subjects if indeed it was not known what those results meant. The committee's letter to the investigator stated:
Why are subjects being offered the test result when the pilot showed no relationship between the allele and AD? If it means nothing, or at least, is not currently known to mean anything, subject autonomy is not served by informing them. We recommend that you include an information waiver-"I understand
IRB
that the results of this test will not be made available to me . . ." This recommendation was adopted by the study investigators and the study is, at the time of writing, accruing subjects.
In retrospect, the committee-or indeed any IRB in similar circumstances-should have added another piece of information to the informed consent. Subjects, even though they will not be informed of the test results, might reasonably expect that someone will keep track of their results in the event that the test, at some later date, becomes clinically useful. Unless investigators plan to keep track of results and notify subjects, participants need to be told upfront that (1) no one will be keeping track of their test results and (2) if the test becomes clinically available that they will need to be retested at that time.
When test results are so preliminary as to be uninformative. patient autonomy is not served by sharing this information with subjects. In the context of gene-hunting studies, we suspect that this will often be the case. If subjects will not be informed of test results, they must be made aware of this fact up-front, at the time when they are approached for consent. This does not imply that test results must be disclosed in all other cases. Rather, the decision to disclose "informative" test results should be based on considerations of respect for persons and beneficence as outlined by Reilly.
Conclusion
IRBs need to assure that genetics protocols undergo the same rigorous review as nongenetics protocols. Members may be unfamiliar with some of the questions concerning issues of validity, value, risk, disclosure, and consent raised by gene localization and identification protocols. Yet the schema provided is based upon the existing IRB review structure. The "critical path" we have suggested for an IRB to follow in reviewing "gene hunting" protocols is accommodated within this structure. IRBs should use the issues addressed by the schema not only to review individual protocols, but also to determine whether they or their institutions ought to develop local policies relevant to such issues as DNA banking, disclosure, or consent.
Our discussion of issues relevant to the wider social impact of protocols suggests that IRBs need to reorient their focus so that it does not rest exclusively on the integrity of individual research subjects, but extends to affected families, groups or other collectivities.
